Related Experiment Video

Updated: Jun 22, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

[Osteogenic factor in pathogenesis of vertebrogenic cardialgia]

E L Sokov, L E Kornilova, V A Filimonov

    Klinicheskaia Meditsina
    |July 2, 2009
    PubMed

    Insights

    Intraosseous blockade (IOB) effectively treats vertebrogenic cardialgia in patients with thoracic osteochondrosis and coronary heart disease (CHD). IOB demonstrated superior therapeutic efficiency compared to paravertebral blockade (PVB).

    Area of Science:

    • Cardiology
    • Neurology
    • Orthopedics

    Background:

    • Thoracic osteochondrosis can cause reflex vertebrocardiac disorders, including vertebrogenic cardialgia.
    • Coronary heart disease (CHD) often coexists with vertebrogenic cardialgia, complicating diagnosis and treatment.
    • Understanding the osteogenic factor's role is crucial for managing these conditions.

    Purpose of the Study:

    • To compare the therapeutic efficiency of intraosseous blockade (IOB) versus paravertebral blockade (PVB) in patients with thoracic osteochondrosis and vertebrogenic cardialgia.
    • To evaluate the impact of IOB on pain syndrome and cardiac function in patients with and without CHD.
    • To elucidate the role of the osteogenic factor in the pathogenesis of vertebrogenic cardialgia.

    Main Methods:

    • A study involving 136 patients with thoracic osteochondrosis and reflex vertebrocardiac disorders.
    • Therapeutic interventions included traditional therapy combined with IOB or PVB.
    • Patient outcomes were assessed using pain scales (visual analog scale, McGill, body diagram), and 24-hour Holter monitoring for cardiac function and rhythm.

    Main Results:

    • Intraosseous blockade (IOB) showed higher therapeutic efficiency than paravertebral blockade (PVB) in patients with thoracic osteochondrosis and CHD.
    • IOB improved pain syndrome parameters and cardiac function in patients with vertebrogenic cardialgia, both with and without CHD.
    • The osteogenic factor was identified as a key element in the development of vertebrogenic cardialgia.

    Conclusions:

    • Intraosseous blockade is a highly effective treatment for vertebrogenic cardialgia associated with thoracic osteochondrosis.
    • The osteogenic factor plays a significant role in the mechanism underlying vertebrogenic cardialgia.
    • Further research into osteogenic contributions to cardiac symptoms is warranted.

    More Related Videos

    Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

    Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

    Published on: June 14, 2016

    Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair09:34

    Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

    Published on: September 7, 2017

    Related Concept Videos

    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Pathophysiology of Cardiac Performance01:29

    Pathophysiology of Cardiac Performance

    Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
    Coronary Artery Disease II: Pathophysiology01:26

    Coronary Artery Disease II: Pathophysiology

    Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...